ArticleContemporary clinical trials communications2020

A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study.

Makito Miyake et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.